Anthony Mancini - 09 Nov 2026 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
12 Nov 2026, 18:00:04 UTC
Prior SEC filing
28 Oct 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jack Anders, as Attorney-in-fact for Anthony Mancini
Filing notes and source

Key filing fact

Anthony Mancini filed Form 4 for Revolution Medicines, Inc. (RVMD) on 12 Nov 2026.

Key facts

  • This page summarizes Anthony Mancini's Form 4 filing for Revolution Medicines, Inc. (RVMD).
  • 5 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 12 Nov 2026, 18:00.

Change

  • Previous filing in this sequence was filed on 28 Oct 2026.
  • Current net transaction value: -$162,200.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002124509 Primary reporting owner

Mancini Anthony

Relationship
Chief Global Commercialization Officer
Address
REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY
Signature
/s/ Jack Anders, as Attorney-in-fact for Anthony Mancini
Signature date
12 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Options Exercise

Transaction value
Shares
+810
Change %
+2%
Price
$33.62*
Shares after
40,575
Date
09 Nov 2026
Ownership
Direct
Footnotes
F1
RVMD transaction

Common Stock

Options Exercise

Transaction value
Shares
+1
Change %
+0%
Price
$102.02*
Shares after
40,576
Date
09 Nov 2026
Ownership
Direct
Footnotes
F1
RVMD transaction

Common Stock

Sale

Transaction value
-$162,200
Shares
-811
Change %
-2%
Price
$200.00
Shares after
39,765
Date
09 Nov 2026
Ownership
Direct
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RVMD transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares
-810
Change %
-0.89%
Price
$0.000000*
Shares after
90,505
Date
09 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
810
Exercise price
$33.62
Footnotes
F1, F3
RVMD transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares
-1
Change %
-0%
Price
$0.000000*
Shares after
26,199
Date
09 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1
Exercise price
$102.02
Footnotes
F1, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026.

Footnote F2

Includes 39,575 restricted stock units.

Footnote F3

Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Footnote F4

One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC remarks

Chief Global Commercialization Officer

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .